ReleaseWire

Global Market Direct's pharmaceuticals report, "Supratek Pharma Inc. - Product Pipeline Review - 2013" provides data on the Supratek Pharma Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Gardena, CA -- With an aim to enhance natural muscle development Muscle King Pro is now available with natural ingredients that assist individuals to experience-proven outcomes in less time. It is actually the very first accurate testosterone enhancer obtainable in the shape of the tablet. It is free of any revolting binders to hinder one’s health and 100% safe to make use of.

Global Markets Direct's, 'Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome). Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

GlobalData's clinical trial report, "Hidradenitis Suppurativa Global Clinical Trials Review, H1, 2014" provides data on the Hidradenitis Suppurativa clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hidradenitis Suppurativa. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hidradenitis Suppurativa. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Sometimes, people who do not take vitamins need to understand the value of them. Sometimes, people who do take them daily need to be reinforced with the idea of how important they are. Diamond Herpanacine of PA is pleased to inform their customers on why they need vitamins in their lives. The most important thing to understand about vitamins is that they carry out the most important functions of the body.

GlobalData's clinical trial report, "Ocular Hypertension Global Clinical Trials Review, H1, 2014" provides data on the Ocular Hypertension clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ocular Hypertension. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ocular Hypertension. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, retinopathy, and neuropathy - is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.

Global Market Direct's pharmaceuticals report, "Basilea Pharmaceutica AG - Product Pipeline Review - 2013" provides data on the Basilea Pharmaceutica AG's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Diakron Pharmaceuticals, Inc. - Product Pipeline Review - 2013" provides data on the Diakron Pharmaceuticals, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, retinopathy, and neuropathy - is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.

Global Markets Direct's, 'Trypanosomiasis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Trypanosomiasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Trypanosomiasis. Trypanosomiasis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "Glucox Biotech AB - Product Pipeline Review - 2013" provides data on the Glucox Biotech AB's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, retinopathy, and neuropathy - is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.

Global Market Direct's pharmaceuticals report, "Adocia - Product Pipeline Review - 2013" provides data on the Adocia's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Bone Fracture - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bone Fracture, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Fracture. Bone Fracture - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

According to statistics released by GBI Research in a recent January report, cosmeceuticals make up the fastest growing sector of the health and beauty industry. The report stated demand for these clinically proven cosmetics and beauty products containing active pharmaceutical ingredients is soaring. Headed by anti-aging cosmeceuticals, this roughly $60 billion worldwide cosmetic industry offers an alternative to costly and often dangerous surgical procedures, promising more dramatic results at lower costs in terms of safety, time and money. To keep up with the demand, Doctor Recommended (drrxus.com) has expanded their line of anti-aging products for public purchase, without a prescription.

PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012

Global Market Direct's pharmaceuticals report, "Sequella, Inc. - Product Pipeline Review - 2013" provides data on the Sequella, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Genzyme Corporation - Product Pipeline Review - 2013" provides data on the Genzyme Corporation's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Gentium S.p.A. - Product Pipeline Review - 2013" provides data on the Gentium S.p.A.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Myeloproliferative Disorders - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Myeloproliferative Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myeloproliferative Disorders. Myeloproliferative Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "Lixte Biotechnology Holdings, Inc. - Product Pipeline Review - 2013" provides data on the Lixte Biotechnology Holdings, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

GlobalData's clinical trial report, "Lupus Nephritis Global Clinical Trials Review, H1, 2014" provides data on the Lupus Nephritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lupus Nephritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lupus Nephritis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'Orthostatic Intolerance - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Orthostatic Intolerance, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Orthostatic Intolerance. Orthostatic Intolerance - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "AlgiPharma AS - Product Pipeline Review - 2013" provides data on the AlgiPharma AS's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.